Get to Know Dr. Richard James Battafarano
Thoracic surgeon Dr. Richard Battafarano has expertise in the treatment of lung cancer and pleural mesothelioma, as well as mediastinal tumors and esophageal cancer.
His goals include providing excellent service for a full range of diseases within the thoracic cavity, utilizing both aggressive and minimally invasive procedures.
At Johns Hopkins, Battafarano is part of the Sidney Kimmel Comprehensive Cancer Center and its lung cancer and esophageal cancer programs. He served previously in the University of Maryland Medical System, where he was chief of the thoracic surgery division.
The focus of Battafarano’s research involves optimal management of lung cancer patients with mediastinal lymph node metastases and surgical outcomes of early-stage lung cancer with neuroendocrine histology.
He also has a special interest in treating emphysema, Barrett’s esophagus and paraesophageal hernias.
Specialties of Dr. Richard James Battafarano
- Thoracic surgery
- Video-assisted thoracoscopic surgery
- Lung cancer
- Barrett’s esophagus
- Paraesophageal hernias
Dr. Richard James Battafarano’s Experience and Medical Education
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- University of Maryland Greenebaum Cancer Center
- Barnes-Jewish Hospital, St. Louis
- Memorial Sloan Kettering Cancer Center (Residency)
- University of Minnesota Medical School (Residency and fellowship)
- Drexel University College of Medicine (M.D.)
Awards and Certifications
- Board certified in thoracic and cardiac surgery
- American Association for Cancer Research (Member)
- Society of Thoracic Surgeons (Member)
- Southern Thoracic Surgical Association (Member)
- American College of Surgeons (Member)
- International Association for the Study of Lung Cancer (Member)
Publications of Dr. Richard James Battafarano
- Lu, Z. et al. (2020, February 26). Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature.
- Bott, M.J. et al. (2019 July). Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery.
- Forde, P.M. et al. (2018, May 24). Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. New England Journal of Medicine.
- Battafarano, R.J. (2016, September 1). Minimally Invasive Esophagectomy: Is There an Advantage? Advances in Surgery.
Thank you for your feedback. Would you like to speak with a Patient Advocate?